Covid-19 living Data

COVID-19 vaccine effectiveness on variants of concern
(Randomized evidence)

If you want to see all variants, please click here

Gamma

Forest plots
(last update: 2022-04-15)

Description of primary studies

Trial	Type	Comparisons		Design	Participants	Sample size	Overall risk of bias Highest assessment	Full description
		Intervention 1	Intervention 2
Gamma Delta NCT04672395 Clover Biopharmaceuticals Inc./Dynavax Bravo L, Lancet, 2022 Full text Commentary Commentary	Protein subunit	SCB-2019	Placebo	RCT Phase 2-3	Healthy adults or with stable chronic conditions, both SARS-CoV-2 seropositive and seronegative, at 31 centers in Belgium, Brazil, Colombia, Philippines, and South Africa.	N=30174	Variant delta: Some concerns Details	Full description
Gamma ISRCTN89951424 AstraZeneca+University of Oxford Clemens S, Nat. Commun., 2021 Full text Commentary Commentary	Non replicating viral vector	ChAdOx1	MenACWY	RCT Phase 3	Adults that were SARS-CoV-2 seronegative and with no history of COVID-19 in six centers in Brazil.	N=10416	Variant gamma: Some concerns Details	Full description
Alpha Gamma Delta NCT04646590 Anhui Zhifei Longcom Biopharmaceutical Dai L, N Engl J Med, 2022 Full text Commentary Commentary	Protein subunit	ZF2001	Placebo	RCT Phase 3	Adults 18 years of age or older with no history of Covid-19, positive tests for SARS-CoV-2 exposure or vaccination, or of congenital or acquired immune deficiency or autoimmune disease at 32 clinical centers across Uzbekistan, Indonesia, Pakistan, Ecuador and China.	N=28904	Variant delta: Some concerns Details	Full description
Alpha Beta Gamma Delta NCT04636697 Medicago Inc Hager K, N Engl J Med, 2022 Full text Full text Commentary	Virus-Like particle	CoVLP	Placebo	RCT Phase 3	Adults including elderly with and without comorbidities, with no previous history of virologically confirmed COVID-19, both seronegative and seropositive, at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA.	N=24141	Variant delta: Some concerns Details	Full description
Alpha Beta Gamma Delta NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 ENSEMBLE2 Full text Full text Commentary	Non replicating viral vector	Ad26.COV2.S Ad26.COV2.S	Placebo	RCT Phase 3	Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA	N=31835	Some concerns Details	Full description
Alpha Gamma NCT04652102; EudraCT 2020-003998-22 CureVac AG Kremsner P, Lancet Infect Dis, 2022 HERALD Full text Commentary	RNA based vaccine	CVnCoV	Placebo	RCT Phase 2-3	Adults with no history of COVID-19 in 47 centers in Belgium, Germany, The Netherlands, Spain, Argentina, Colombia, Dominican Republic, Mexico, Panama and Peru	N=39680	Some concerns Details	Full description
Beta Gamma NCT04764422 The Government Pharmaceutical Organization (GPO); PATH; Dynavax Pitisuttithum P, medRxiv, 2021 Full text Commentary Commentary	Inactivated virus	NDV-HXP-S 1mcg NDV-HXP-S 1mcg + CpG1018 NDV-HXP-S 3mcg NDV-HXP-S 3mcg + CpG1018 NDV-HXP-S 10mcg NDV-HXP-S 1mcg	Placebo	RCT Phase 1	Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand	N=210	Some concerns Details	Full description